Deviation Backlog Reduction: Balancing Investigation Depth, Closure Speed, and Justifiable Decisions
Practical strategies for reducing pharmaceutical deviation backlogs without sacrificing investigation quality — covering risk-based depth, defensible closure, CAPA, and inspection readiness.
Instructor
Charles H. Paul
President, CHP Consulting LLC — Regulatory Compliance & Operational Excellence
What You'll Learn
About the event
About this event
Deviation management remains one of the most visible indicators of quality system health within regulated pharmaceutical, biotechnology, medical device, and combination product organizations. While deviations themselves are expected in any complex operation, the accumulation of unresolved investigations often signals deeper systemic issues involving resource allocation, investigation practices, decision-making frameworks, quality culture, procedural complexity, and operational discipline.
Many organizations struggle to balance two competing expectations. Regulatory agencies expect thorough investigations that identify true root causes and implement effective corrective actions. At the same time, business operations require timely closure of records to avoid excessive backlog growth, delayed product disposition decisions, inspection exposure, and resource consumption. Organizations frequently find themselves trapped between lengthy investigations that consume significant resources and rapid closures that may be difficult to defend during regulatory inspections.
As deviation inventories grow, quality organizations often become increasingly reactive. Investigators become overloaded, investigations lose focus, closure timelines continue to expand, and management visibility decreases. The result is often a self-reinforcing cycle where backlogs continue to increase despite significant efforts to reduce them.
This webinar examines practical strategies for reducing deviation backlogs without sacrificing investigation quality or regulatory defensibility. Participants will learn how to establish risk-based investigation frameworks, improve decision-making consistency, focus investigative resources appropriately, and implement sustainable approaches that improve both closure performance and investigation effectiveness.
Regulatory investigators increasingly examine not only individual deviations but also the overall health of the deviation management system. Large numbers of aging investigations, repeated extensions, weak root cause determinations, inconsistent classifications, ineffective CAPAs, and poor closure discipline can all become indicators of broader quality system weaknesses. During inspections, deviation backlogs often serve as a gateway into discussions regarding management oversight, quality culture, investigation effectiveness, and risk management practices.
By the conclusion of the webinar, attendees will understand how to evaluate investigation depth requirements, improve closure efficiency, strengthen decision quality, reduce aging investigations, and create a balanced deviation management system that supports both compliance and operational performance.
Code: FDB1605
Curriculum
Requirements
- Working in pharmaceutical, biotechnology, medical device, or other regulated manufacturing
- Involvement in quality systems, deviation management, CAPA, or compliance functions
- Applicable to quality directors, QA managers, deviation investigators, site leaders, and compliance professionals
Who Should Attend
Vice Presidents of Quality, Quality Directors, Quality Assurance Managers, Quality Systems Managers, Compliance Directors, Manufacturing Directors, Operations Directors, Site Leaders, Plant Managers, Quality Engineers, Deviation Investigators, CAPA Coordinators, Validation Professionals, Regulatory Affairs Professionals, Continuous Improvement Leaders, Operational Excellence Managers, Technical Services Personnel, Manufacturing Supervisors, Quality Auditors, and GMP Consultants.
Areas Covered
Meet Your Instructor

Charles H. Paul
President, CHP Consulting LLC — Regulatory Compliance & Operational Excellence
Charles H. Paul is President of CHP Consulting LLC, a regulatory compliance, operational excellence, training, and technical documentation consulting firm supporting pharmaceutical, biotechnology, medical device, and advanced therapy organizations worldwide. With more than 30 years of experience in regulated manufacturing environments, Charles specializes in helping organizations build sustainable quality systems that support compliance, operational performance, workforce effectiveness, and inspection readiness. His experience includes GMP quality systems, manufacturing operations, technical training development, process validation, deviation management, CAPA systems, operational excellence, documentation systems, and regulatory inspection preparation. Charles has supported organizations implementing new technologies, expanding manufacturing operations, establishing quality infrastructures, and preparing for complex regulatory inspections. He is a recognized author, speaker, and consultant who has delivered numerous webinars and seminars on GMP compliance, quality systems, human performance improvement, technical documentation, inspection readiness, and operational excellence throughout the life sciences industry.
Event Details
Format
Recorded Webinar
Duration
1 hour
Certificate
Included
Access
Lifetime
Related Events
Digital Quality Metrics and AI/ML Analytics: Building a Continuous-Improvement Framework that Aligns with Regulatory Expectations
Learn how AI/ML and real-time digital quality metrics build a continuous-improvement framework aligned with FDA regulatory expectations, 21 CFR Part 11, and GAMP®5.

AI in GMP: What the FDA Is Already Expecting - Before You Ask
FDA already expects GMP compliance for AI systems. Learn how existing validation, data integrity, and oversight rules apply—before regulators come calling.

HPLC Analytical Method Development and Validation
Master HPLC instrument and method validation to meet US EPA and FDA requirements for pharmaceutical analysis.